Geojit IPO report on Glenmark Life Sciences
Glenmark Life Sciences Limited (GLSL), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. As of March 31st, 2021, they had a portfolio of 120 molecules and are adding on average 8-10 new molecules annually. They are also providing contract development and manufacturing operations (CDMO) services to pharmaceutical companies.
Valuation and Outlook
We assign a “Subscribe” rating for the issue on a long-term basis considering its strong focus on R&D, expansion plans(1726.6KL when completed), growth opportunity in CDMO services and expanding complex API portfolio.
For all IPO stories, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More